Molbio Diagnostics mops up Rs 281 crore from anchor investors ahead of IPO

Pointofcare diagnostics company Molbio Diagnostics Ltd backed by Temasek and Motilal Oswal Private Equity raised Rs 2815 crore from anchor investors ahead of its initial public offering IPOThe company allotted 3488 lakh equity shares to 33 anchor investors at Rs 807 apiece the upper end of the price band according to a circular uploaded on the BSE website late night on FridayAmong the largest anchor investors are Goldman Sachs BlackRock Global Funds Mirae Asset Nippon India Mutual Fund ICICI Prudential Mutual Fund Kotak Mutual Fund Tata Mutual Fund WhiteOak Capital Bajaj Life Insurance and HDFC Life InsuranceDomestic mutual funds received 2354 lakh shares accounting for 6751 per cent of the anchor book through 19 schemes of nine fund housesThe IPO with a price band of Rs 768807 per share will open for public subscription on August 10 and conclude on August 12 The initial share sale is estimated at Rs 904 crore to Rs 940 crore at the lower and upper ends of the price band respectivelyThe Goabased companys IPO comprises a fresh issue of shares worth up to Rs 200 crore and an offer for sale OFS of up to 9166 lakh equity shares by existing shareholdersUnder the OFS Exxora Trading LLP Dr Chandrasekhar Bhaskaran Nair India Business Excellence Fund III Gopalkrishna Mangalore Kini J Guru Dutt Gopalakrishna Sampathgiri Sangeetha M Kini M A Usha Rani M A Rohit Shruthi G Kini and several other shareholders will divest their stakesThe company proposes to utilise Rs 106 crore from the fresh issue proceeds towards capital expenditure for setting up infrastructure for an RampD facility Centre of Excellence and connected office spaceAnother Rs 72 crore will be deployed towards the purchase of plant machinery and other equipment for its Goa Unit I Goa Unit II and Visakhapatnam unit while the remaining funds will be used for general corporate purposesAt the upper end of the price band Molbio Diagnostics is expected to command a postissue market valuation of around Rs 9300 croreIncorporated in 2000 Molbio Diagnostics is a pointofcare diagnostics company offering molecular testing for 30 diseases including tuberculosis COVID HIV HPV and Hepatitis B and CIts Truenat platform patented in more than 100 countries for diagnosis of multiple infectious and noncommunicable diseases is a pointofcare polymerase chain reaction PCR platform The batteryoperated platform can be deployed in resourcelimited settings and facilitates decentralised diagnosis within an hourThe company has six manufacturing facilities in India two in Goa two in Bengaluru and one each in Visakhapatnam and PuneAs of March 31 2026 Molbios installed capacity stood at 5400 devices per annum and 39 crore Truenat test kits annuallyOn the financial front the companys revenue from operations stood at Rs 1445 crore in fiscal 2026 and profit at Rs 164 crore during the periodThe companys shares are proposed to be listed on the BSE and NSE on August 17Kotak Mahindra Capital Company IIFL Capital Services Jefferies India and Motilal Oswal Investment Advisors are the bookrunning lead managers to the issueThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever